Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 9/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.95 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL4380284 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL145687 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56351 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL56352 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL6388781 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL7759844 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL13785162 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL3406205 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL40651 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA | |
| (+)-Tranylcypromine SCHEMBL1649712 | 0.97 | KDM1A (1.00) | KDM1AMAOBMAOATAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| EP-2572192-A2 | A GENERAL MASS SPECTROMETRY ASSAY USING CONTINUOUSLY ELUTING CO-FRACTIONATING REPORTERS OF MASS SPECTROMETRY DETECTION EFFICIENCY | The UAB Research Foundation (US) | 2013-03-27 | — | — | EP | claimed |
| WO-2011146521-A2 | A GENERAL MASS SPECTROMETRY ASSAY USING CONTINUOUSLY ELUTING CO-FRACTIONATING REPORTERS OF MASS SPECTROMETRY DETECTION EFFICIENCY | THE UAB RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | WO | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| EP-3471743-B1 | STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL | FRED HUTCHINSON CANCER CENTER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240245647-A1 | ISOMEROHYDROLASE INHIBITOR FOR TREATMENT OF ATROPHIC FORM OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2024086595-A2 | SYSTEMS AND METHODS FOR GENE THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-117320721-A | Novel compounds comprising a novel class of thyroxine transporter ligands for the treatment of common age-related complications | 纽约哥伦比亚大学董事会 | 2023-12-29 | — | — | CN | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230312687-A1 | CELL-FREE ANIMAL COLLAGEN, METHODS OF PRODUCTION AND USES THEREOF | ALEPH FARMS LTD. (IL) | 2023-10-05 | — | — | US | disclosed |
| CN-111527084-B | Isofuranone compounds useful as HPK1 inhibitors | 百时美施贵宝公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
| EP-0759932-A4 | COLLAGEN FROM CELL CULTURES | ORGANO GENESIS INC (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
| EP-0759932-A1 | COLLAGEN FROM CELL CULTURES | ORGANOGENESIS INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031473-A1 | COLLAGEN FROM CELL CULTURES | ORGANOGENESIS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5153318-A | Viricides for hepatitis and human t-cell leukemia/lymphoma viruses | BURROUGHS WELLCOME CO. (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0421739-A1 | 3'-azido purine nucleoside | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| US-3961073-A | 2-PHENYL-CYCLOPROPYLAMINE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245647-A1 | ISOMEROHYDROLASE INHIBITOR FOR TREATMENT OF ATROPHIC FORM OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | ALDH1A2, HSD17B14, SPINT2 | MAOB 185/4885MAOA 271/4885KDM1A 2414/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | MAOB 1517/4885MAOA 2814/4885KDM1A 4682/4885 |
| US-20230312687-A1 | CELL-FREE ANIMAL COLLAGEN, METHODS OF PRODUCTION AND USES THEREOF | COL2A1, COL14A1, COL1A1 | MAOB 2190/4885MAOA 993/4885KDM1A 547/4885 |
| US-20240150297-A1 | NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, APOB, TSHR | MAOB 1040/4885MAOA 1566/4885KDM1A 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.